334 related articles for article (PubMed ID: 26511242)
21. Pathophysiology and Treatment of Canavan Disease.
Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
[No Abstract] [Full Text] [Related]
22. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
23. Loss of central auditory processing in a mouse model of Canavan disease.
von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
[TBL] [Abstract][Full Text] [Related]
24. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G
Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081
[TBL] [Abstract][Full Text] [Related]
25. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
[TBL] [Abstract][Full Text] [Related]
26. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
27. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
28. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase.
Chakraborty G; Mekala P; Yahya D; Wu G; Ledeen RW
J Neurochem; 2001 Aug; 78(4):736-45. PubMed ID: 11520894
[TBL] [Abstract][Full Text] [Related]
29. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.
Baslow MH; Guilfoyle DN
Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
31. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
32. Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.
Appu AP; Moffett JR; Arun P; Moran S; Nambiar V; Krishnan JKS; Puthillathu N; Namboodiri AMA
Front Mol Neurosci; 2017; 10():161. PubMed ID: 28626388
[TBL] [Abstract][Full Text] [Related]
33. Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders.
Feng L; Chao J; Ye P; Luong Q; Sun G; Liu W; Cui Q; Flores S; Jackson N; Shayento ANH; Sun G; Liu Z; Hu W; Shi Y
Adv Sci (Weinh); 2023 Aug; 10(23):e2206910. PubMed ID: 37271923
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.
Zaroff S; Leone P; Markov V; Francis JS
Mol Cell Neurosci; 2015 Mar; 65():143-52. PubMed ID: 25766789
[TBL] [Abstract][Full Text] [Related]
35. The pathogenesis of, and pharmacological treatment for, Canavan disease.
Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
[TBL] [Abstract][Full Text] [Related]
36. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.
Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM
Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978
[TBL] [Abstract][Full Text] [Related]
37. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
[TBL] [Abstract][Full Text] [Related]
38. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
[TBL] [Abstract][Full Text] [Related]
39. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
40. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]